,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['bcsm', 'breast']
looking forward to the #asco22 plenary sessions - destiny 04 trial - tdxd versus tpc in her-2 low breast cancer - we were fortunate to be part of this important trial #clecliniccancer #bcsm 
Prof. & Chair Dept. of Heme and Oncology @ClevelandClinic @NRGonc Deputy Editor @JCOOP_ASCO Tweets are mine. No act of #Kindness is ever wasted #CleClinicCancer